Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.48 |
| ▸ | PDE2A | O00408 | 3/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 10/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 10/20 | 0.46 |
| ▸ | CYP17A1 | P05093 | 5/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.46 |
| ▸ | RAF1 | P04049 | 1/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14905509 | 0.85 | DYRK1A (0.44) | PDE10APDE2ACYP19A1RAF1PDGFRB | |
| SCHEMBL14905518 | 0.78 | PDE2A (0.47) | PDE10APDE2A | |
| SCHEMBL15886134 | 0.76 | FGFR3 (0.57) | — | |
| SCHEMBL28867703 | 0.74 | PTPN11 (0.38) | PDE10APDE2APDGFRBPDGFRA | |
| SCHEMBL14905513 | 0.73 | FGFR1 (0.43) | — | |
| SCHEMBL14905395 | 0.73 | FGFR1 (0.46) | PDE10A | |
| SCHEMBL14905375 | 0.73 | PDGFRB (0.60) | PDE10APDE2ACYP11B1CYP11B2CYP17A1 | |
| SCHEMBL14905348 | 0.72 | EGFR (0.41) | PDE10APDE2APDGFRBPDGFRA | |
| SCHEMBL4507986 | 0.72 | MAP4K4 (0.41) | PDE10APDGFRBPDGFRA | |
| SCHEMBL4502318 | 0.72 | KCNH2 (0.43) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2776436-B1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LTD (GB) | 2019-03-13 | — | — | EP | disclosed |
| US-9757364-B2 | Naphthyridine derivative compounds | ASTEX THERAPEUTICS LTD (GB) | 2017-09-12 | — | — | US | disclosed |
| US-9757364-B2 | Naphthyridine derivative compounds | ASTEX THERAPEUTICS LTD (GB) | 2017-09-12 | — | — | US | disclosed |
| US-20170105978-A1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2017-04-20 | — | — | US | disclosed |
| US-20170105978-A1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2017-04-20 | — | — | US | disclosed |
| US-9527844-B2 | Naphthyridine derivative compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2016-12-27 | — | — | US | disclosed |
| US-9527844-B2 | Naphthyridine derivative compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2016-12-27 | — | — | US | disclosed |
| US-20160108034-A1 | NAPHTHYRIDINE DERIVATIVE COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2016-04-21 | — | — | US | disclosed |
| US-9309241-B2 | Naphthyridine derivative compounds | ASTEX THERAPEUTICS LTD (GB) | 2016-04-12 | — | — | US | disclosed |
| US-9309241-B2 | Naphthyridine derivative compounds | ASTEX THERAPEUTICS LTD (GB) | 2016-04-12 | — | — | US | disclosed |
| US-20150057293-A1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2015-02-26 | — | — | US | disclosed |
| US-20150057293-A1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2015-02-26 | — | — | US | disclosed |
| WO-2013061077-A1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2013-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057293-A1 | NEW COMPOUNDS | NQO1, NTPCR, NDC1 | PDE10A 2833/4885PDE2A 2867/4885CYP11B1 299/4885 |
| US-20170105978-A1 | NEW COMPOUNDS | NQO1, NTPCR, NDC1 | PDE10A 2833/4885PDE2A 2867/4885CYP11B1 299/4885 |
| US-20160108034-A1 | NAPHTHYRIDINE DERIVATIVE COMPOUNDS | NQO1, NDC1, NTPCR | PDE10A 3827/4885PDE2A 3005/4885CYP11B1 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.